全文获取类型
收费全文 | 797篇 |
免费 | 37篇 |
国内免费 | 14篇 |
专业分类
儿科学 | 44篇 |
妇产科学 | 4篇 |
基础医学 | 68篇 |
口腔科学 | 21篇 |
临床医学 | 133篇 |
内科学 | 117篇 |
皮肤病学 | 8篇 |
神经病学 | 19篇 |
特种医学 | 195篇 |
外科学 | 42篇 |
综合类 | 32篇 |
预防医学 | 24篇 |
眼科学 | 2篇 |
药学 | 124篇 |
中国医学 | 2篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 8篇 |
2017年 | 12篇 |
2016年 | 10篇 |
2015年 | 10篇 |
2014年 | 24篇 |
2013年 | 18篇 |
2012年 | 10篇 |
2011年 | 15篇 |
2010年 | 20篇 |
2009年 | 20篇 |
2008年 | 8篇 |
2007年 | 18篇 |
2006年 | 11篇 |
2005年 | 16篇 |
2004年 | 19篇 |
2003年 | 22篇 |
2002年 | 22篇 |
2001年 | 14篇 |
2000年 | 13篇 |
1999年 | 27篇 |
1998年 | 42篇 |
1997年 | 49篇 |
1996年 | 39篇 |
1995年 | 44篇 |
1994年 | 25篇 |
1993年 | 26篇 |
1992年 | 18篇 |
1991年 | 21篇 |
1990年 | 18篇 |
1989年 | 15篇 |
1988年 | 24篇 |
1987年 | 23篇 |
1986年 | 22篇 |
1985年 | 19篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 18篇 |
1981年 | 12篇 |
1980年 | 22篇 |
1979年 | 4篇 |
1978年 | 12篇 |
1977年 | 22篇 |
1976年 | 12篇 |
1975年 | 8篇 |
1963年 | 2篇 |
1943年 | 1篇 |
排序方式: 共有848条查询结果,搜索用时 31 毫秒
31.
Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines 总被引:1,自引:0,他引:1
Platelet-derived growth factors (PDGF) are potent regulators of cell proliferation. The three isoforms of PDGF AA, AB, and BB are encoded by two genes: PDGF A and PDGF B. The v-sis oncogene is homologous to the PDGF-B gene. v-sis can transform cells that express the appropriate PDGF receptors. Two different types of receptors, PDGF-alpha and PDGF- beta, also encoded by two genes, have been identified. We show that two cell lines. SMS-SB and NALM-6, both derived from pre-B-cell acute lymphocytic leukemias, express the PDGF-A chain gene, and one of them, SMS-SB, releases PDGF-A chains into the media. The SMS-SB cells also express the PDGF-beta receptor, whereas NALM-6 cells express the PDGF- alpha receptor and bind PDGF. This extends the possible targets for PDGF to the B-cell lineage lymphocytes. 相似文献
32.
Two patients with hairy cell leukemia with massive splenomegaly and severe pancytopenia were treated with recombinant alpha-A interferon (IFN-alpha-2a). There was no significant response to a trial of IFN- alpha-2a (11 and 20 weeks) with respect to blood counts or spleen size. Subsequent treatment with 2'-deoxycoformycin (dCF) for 8 consecutive weeks (4 mg/m2/wk) resulted in normalization of spleen size and a normalization of peripheral blood counts and bone marrow in one patient. The second patient demonstrated a reduction in spleen size and improved blood counts following 9 weeks of dCF therapy but eventually became refractory. This demonstrates that dCF is non-cross-resistant with interferon and confirms the efficacy of dCF in nonsplenectomized patients. 相似文献
33.
34.
35.
36.
G. L. NIELSEN K. L. FAARVANG† B. S. THOMSEN‡ K. L. TEGLBJÆRG L. T. JENSEN‡ T. M. HANSEN† H. H. LERVANG§ E. B. SCHMIDT§ J. DYERBERG¶ E. ERNST§ 《European journal of clinical investigation》1992,22(10):687-691
STUDY OBJECTIVE: To determine the effect of dietary supplementation with n-3 polyunsaturated fatty acids (n-3 PUFA) on disease variables in patients with rheumatoid arthritis. DESIGN: Multicenter, randomized, placebo controlled, double blind. SETTING: Three Danish hospital Departments of Rheumatology. PATIENTS: Fifty-one patients with active rheumatoid arthritis. INTERVENTION: Random allocation to 12 weeks of treatment with either six n-3 PUFA capsules (3.6 g) or six capsules with fat composition as the average Danish diet. MAIN RESULTS: Significant improvement of morning stiffness and joint tenderness. No significant effect on the four other assessed clinical parameters. No serious side effects. CONCLUSIONS: Dietary supplementation with n-3 PUFA in patients with rheumatoid arthritis improved two out of six patient reported disease parameters. Further studies are needed to clarify the more precise role of n-3 PUFA in the treatment of rheumatoid arthritis. 相似文献
37.
38.
39.
UMAER NASEER BJ
RG HALDORSEN STLE TOFTELAND KRISTIN HEGSTAD FLEMMING SCHEUTZ GUNNAR SKOV SIMONSEN ARNFINN SUNDSFJORD 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2009,117(7):526-536
Nationwide, CTX‐M‐producing clinical Escherichia coli isolates from the Norwegian ESBL study in 2003 (n=45) were characterized on strain and plasmid levels. BlaCTX‐M allele typing, characterization of the genetic environment, phylogenetic groups, pulsed field gel electrophoresis (PFGE), serotyping and multilocus sequence typing were performed. Plasmid analysis included S1‐nuclease‐PFGE, polymerase chain reaction‐based replicon typing, plasmid transfer and multidrug resistance profiling. BlaCTX‐M‐15 (n=23; 51%) and blaCTX‐M‐14 (n=11; 24%) were the major alleles of which 18 (78%) and 6 (55%), respectively, were linked to ISEcp1. Thirty‐two isolates were of phylogenetic groups B2 and D. Isolates were of 29 different XbaI‐PFGE‐types including six regional clusters. Twenty‐three different O:H serotypes were found, dominated by O25:H4 (n=9, 20%) and O102:H6 (n=9, 20%). Nineteen different STs were identified, where ST131 (n=9, 20%) and ST964 (n=7, 16%) were dominant. BlaCTX‐M was found on ≥100 kb plasmids (39/45) of 10 different replicons dominated by IncFII (n=39, 87%), FIB (n=20, 44%) and FIA (n=19, 42%). Thirty‐nine isolates (87%) displayed co‐resistance to other classes of antibiotics. A transferable CTX‐M phenotype was observed in 9/14 isolates. This study reveals that the majority of CTX‐M‐15‐expressing strains in Norway are part of the global spread of multidrug‐resistant ST131 and ST‐complex 405, associated with ISEcp1 on transferrable IncFII plasmids. 相似文献
40.
Priego EM von Frijtag Drabbe Kuenzel J IJzerman AP Camarasa MJ Pérez-Pérez MJ 《Journal of medicinal chemistry》2002,45(16):3337-3344
1H,3H-Pyrido[2,1-f]purine-2,4-diones, which can be described as fused xanthine structures, have been synthesized by a novel synthetic procedure, and their affinities for the human adenosine A(1), A(2A), and A(3) receptors have been evaluated in radioligand binding studies. The synthetic procedure employed was developed in our laboratory and involved a two-step one-pot reaction that consists of the treatment of 6-aminouracil derivatives with N-bromosuccinimide to generate a 5,5-dibromo-6-imino intermediate that reacts "in situ" with pyridine, 4-methoxypyridine, 4-tert-butylpyridine, or 4-phenylpyridine to afford the corresponding 1H,3H-pyrido[2,1-f]purine-2,4-diones (2-5). Functionalization at the N(3) position in compounds 2-5 was performed by reaction with DBU and different alkyl, alkenyl, alkynyl, or benzyl halides. Binding studies at human adenosine A(1), A(2A), and A(3) receptors revealed significant antagonist effects in the low nanomolar range, in particular against the A(3) receptor. Thus, the 1-benzyl-3-propyl-1H,3H-pyrido[2,1-f]purine-2,4-dione derivative 6, which can be considered a lead compound in this series, exhibited a K(i) value of 4.0 +/- 0.3 nM against the hA(3) receptor. Because xanthine derivatives have traditionally been considered poor A(3) antagonists, the described pyrido[2,1-f]purine-2,4-dione derivatives represent a new family of adenosine receptor antagonists which deserves further exploration. 相似文献